# **Valbenazine in Tardive Dyskinesia**



©2024 Neurocrine Biosciences, Inc. All Rights Reserved.

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP	
Table of Cor	ntents					
		Introduction to	Tardive Dyskinesia	$\bigcirc$		
		Introduc	tion to Valbenazine	$\bigcirc$		

KINECT 3 (NCT02274558): Double-blind, Placebo-controlled Phase 3 Study

KINECT 3 (NCT02274558): Double-blind Extension Period

KINECT 4 (NCT02405091): Long-term, Open-label Study

Backup

 $(\rightarrow)$ 

TARDIVE DYSKINESIA

VALBENAZINE

KINECT 3

**KINECT 3 EXTENSION** 

**KINECT 4** 

BACKUP


# Introduction to Tardive Dyskinesia

# **TD Pathophysiology**

- The mechanism underlying TD is complex, and the exact cause has not been fully elucidated<sup>1-4</sup>
- A leading theory is the upregulation and subsequent hypersensitivity of brain dopamine D<sub>2</sub> receptors following prolonged exposure to DRBAs<sup>1</sup>
- Additional hypotheses include DRBA-induced:
  - Oxidative stress from free radical formation<sup>2</sup>
  - Dysfunction of GABA and/or serotonin pathways<sup>3,4</sup>

#### Healthy Brain Function

#### **Tardive Dyskinesia**






DRBA, dopamine receptor-blocking agent; GABA, gamma-aminobutyric acid; TD, tardive dyskinesia; VMAT2, vesicular monoamine transporter type 2.

1. Klawans H, et al. Acta Neurol Scand. 1970;46(4):409-441. 2. Pai BN, et al. Biol Psychiatry. 1994;36(7):489-491. 3. Segman RH, et al. Mol Psychiatry. 2001;6(2):225-229. 4. Gittis AH, et al. J Neurosci. 2011;31(44):15727-15731.

# TD is a Clinically Distinct, Delayed DRBA-induced Movement Disorder<sup>1</sup>

Defined as abnormal, involuntary movements of the tongue, jaw, trunk, or extremities that develop in association with medications that block postsynaptic dopamine receptors




DRBA, dopamine receptor-blocking agent; FGA, first-generation antipsychotic; OBL, oral-buccal-lingual; SGA, second-generation antipsychotic; TD, tardive dyskinesia. \*Movements are distinctly different from the rhythmic tremors (3–6 Hz) commonly seen in drug-induced parkinsonism.<sup>1</sup>

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. American Psychiatric Association; 2022.

**TD Prevalence**<sup>2†</sup>

### 

### **TD is Associated With Prolonged DRBA Treatment**



### TD Annual Incidence<sup>1\*</sup>

~5 million patients in the United States are treated with antipsychotics<sup>3</sup> ≥600,000 patients may have TD<sup>3,4‡</sup>



DRBA, dopamine receptor-blocking agent; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic; TD, tardive dyskinesia.


\*2018 meta-analysis of 57 randomized controlled trials (FGA-SGA studies, N=10,706; SGA-SGA studies, N=9153). †2017 meta-analysis of 41 studies (N=11,493). ‡Estimate from a 2014 analysis of prescriptions and incidence rates. 1. Carbon M, et al. *World Psychiatry*. 2018;17(3):330-340. 2. Carbon M, et al. *J Clin Psychiatry*. 2017;78(3):e264-e278. 3. Cloud LJ, et al. *Neurotherapeutics*. 2014;11:166-176. 4. Data on file. Neurocrine Biosciences, Inc.

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP	

### **Diagnosis of TD**

• Health care providers use clinical evaluation and medical history to diagnose TD

• TD may appear in patients also experiencing other DRBA-induced movement disorders



DRBA, dopamine receptor-blocking agent; TD, tardive dyskinesia; LAI, long-acting injectable.


\*Dyskinesia may remit with continued withdrawal. A diagnosis of TD may be warranted if the dyskinesia persists for at least 4 weeks. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision*. American Psychiatric Publishing; 2022.

### 

# **Scoring AIMS**

AIMS is a 12-item, clinician-rated scale used to assess TD severity

	Facial and Oral Movements	None	Minimal	Mild	Moderate	Severe
1.	Muscles of facial expression	0	1	2	3	4
2.	Lips and perioral area	0	1	2	3	4
3.	Jaw	0	1	2	3	4
4.	Tongue	0	1	2	3	4
	Extremity Movements	None	Minimal	Mild	Moderate	Severe
5.	Upper (arms, wrists, hands, fingers)	0	1	2	3	4
6.	Lower (legs, knees, ankles, toes)	0	1	2	3	4
	Trunk Movements	None	Minimal	Mild	Moderate	Severe
7.	Neck, shoulders, hips	0	1	2	3	4
$\left( \right)$	AIMS Total Dyski	nesia S	core=Sun	n of Ite	ms 1–7	
8. 9.	Global severity of abnormal mov	10. 11–12	Aware 2. Denta	eness al status		



AIMS, Abnormal Involuntary Movement Scale; TD, tardive dyskinesia.

0=no dyskinesia; 1=low amplitude, present during some, but not most of, the exam; 2=low amplitude and present during most of the exam (or moderate amplitude and present during some of the exam); 3=moderate amplitude and present during most of exam; or 4=maximal amplitude and present during most of exam.

Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised 1976. (DHEW publication number ADM 76-338). National Institute of Mental Health, Psychopharmacology Research Branch; 1976:534-537.

# **2020 APA Guideline: TD Recommendations**

201	iew <sup>1</sup>	2020 APA Guideline Recommendations <sup>2</sup>			
Intervention	Category	Conclusion	Intervention	Category	Conclusion
VBZ	LEVEL	Recommended as first-line treatment	Reversible VMAT2	1B	Recommended in moderate to severe, or disabling TD
Deutetrabenazine	LEVEL A	Recommended as <b>first-line treatment</b>	inhibitor for treatment of TD	N/A*	Can be considered in mild TD based on factors such as patient preference, associated impairment, or effect on psychosocial functioning



AAN, American Academy of Neurology; APA, American Psychiatric Association; DRBA, dopamine receptor–blocking agent; N/A, not available; TD, tardive dyskinesia; VMAT2, vesicular monoamine transporter type 2; VBZ, valbenazine. 2013 AAN guidelines were published before available treatments were approved for adults with TD. 2018 systematic review aimed to update the evidence-based recommendations and provide a practical algorithm for treatment of TD.

#### \*GRADE ratings were only assigned for primary guideline statements.

1. Bhidayasiri R, et al. *J Neurol Sci.* 2018;389:67-75. 2. American Psychiatric Association. Clinical practice guidelines for treatment of patients with schizophrenia. Accessed on March 8, 2023. https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841.



**TARDIVE DYSKINESIA** VALBENAZINE **KINECT 3 KINECT 3 EXTENSION KINECT 4** BACKUP **Introduction to Valbenazine** 


KINECT 3

KINECT 3 EXTENSION

6

### **Valbenazine Mechanism of Action**

The mechanism of action of valbenazine in the treatment of TD is unclear, but is thought to be mediated through the reversible inhibition of VMAT2<sup>2</sup>



#### TD, tardive dyskinesia; VBZ, valbenazine; VMAT2, vesicular monoamine transporter type 2.

1. Margolese HC, et al. Can J Psychiatry. 2005;50:541-547. 2. INGREZZA® (valbenazine). Package insert. Neurocrine Biosciences, Inc., 2021.

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP	ŝ
Valber	azine Overview		Valbenazine <sup>1</sup>			
	Typical dosage range		40, 60, 80 mg, 1 cap	sule once daily		
	2 Formulations		INGREZZA INGREZZA® S			
	Renal Impairment or Geriatric Use		No dose adju	ustment		
	Hepatic Impairment		Maximum 40r	mg daily		
	Effect of Food		Taken with or v	with food		
	Single Active Metabolite	[+]-α-HT Selective for VMAT2 only, binding affinity for dopamir adrenergic, or histamin	with no appreciable nergic, serotonergic,			
	Elimination half-life		15–22 hc	ours		

HTBZ, dihydrotetrabenazine; VBZ, valbenazine; VMAT2, vesicular monoamine transporter type 2. 1. Keepers GA, et al. *The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia*. 3rd ed. Washington, DC: American Psychiatric Association; 2020. https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841. Accessed April 20, 2021. 2. INGREZZA® (valbenazine) [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.; 2021.



### 

### **INGREZZA and INGREZZA SPRINKLE Important Safety Information**

Depression and Suicidality in Patients with Huntington's Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington's disease.

#### CONTRAINDICATIONS

INGREZZA and INGREZZA SPRINKLE are contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA or INGREZZA SPRINKLE.

#### WARNINGS & PRECAUTIONS Hypersensitivity Reactions

Hypersensitivity reactions, including cases of angioedema involving the larynx, glottis, lips, and eyelids, have been reported in patients after taking the first or subsequent doses of INGREZZA. Angioedema associated with laryngeal edema can be fatal. If any of these reactions occur, discontinue INGREZZA or INGREZZA SPRINKLE.

**Somnolence and Sedation**: INGREZZA and INGREZZA SPRINKLE can cause somnolence and sedation. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA or INGREZZA SPRINKLE.



NMS, neuroleptic malignant syndrome; TD, tardive dyskinesia; VBZ, valbenazine; VMAT2, vesicular monoamine transporter type 2. INGREZZA® (valbenazine). Package insert. Neurocrine Biosciences, Inc., San Diego, CA.

### **INGREZZA and INGREZZA SPRINKLE Important Safety Information**

**QT Prolongation**: INGREZZA and INGREZZA SPRINKLE may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA and INGREZZA SPRINKLE should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

**Neuroleptic Malignant Syndrome**: A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission, including INGREZZA. The management of NMS should include immediate discontinuation of INGREZZA or INGREZZA SPRINKLE, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems. If treatment with INGREZZA or INGREZZA SPRINKLE is needed after recovery from NMS, patients should be monitored for signs of recurrence.

**Parkinsonism**: INGREZZA and INGREZZA SPRINKLE may cause parkinsonism. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA or INGREZZA SPRINKLE treatment in patients who develop clinically significant parkinson-like signs or symptoms.

#### **ADVERSE REACTIONS**

The most common adverse reaction in patients with tardive dyskinesia ( $\geq$ 5% and twice the rate of placebo) is somnolence. The most common adverse reactions in patients with chorea associated with Huntington's disease (( $\geq$ 5% and twice the rate of placebo) are somnolence/lethargy/sedation, urticaria, and insomnia.

TARDIVE DYSKINESIA

VALBENAZINE

KINECT 3

**KINECT 3 EXTENSION** 


KINECT 4

# KINECT 3 (NCT02274558): Double-blind, Placebo-controlled Phase 3 Study

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	<b>KINECT 3 EXTENSION</b>	KINECT 4	BACKUP	

### **KINECT 3: Study Design**

Randomized, double-blind, placebo-controlled, fixed-dose study



AIMS, Abnormal Involuntary Movement Scale; CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; PBO, placebo; SAP, statistical analysis plan; TD, tardive dyskinesia; VBZ, valbenazine. \*80-mg group received 40 mg for the first week. Hauser RA, et al. *Am J Psychiatry*. 2017;174(5):476-484. **KINECT 3 EXTENSION** 

### **KINECT 3: Eligibility Criteria**<sup>1,2</sup>



- Age 18–85 years
- Schizophrenia, schizoaffective disorder, or mood disorder\* diagnosed ≥3 months before screening
- TD ≥3 months before screening
- Moderate or severe TD based on qualitative assessment of screening video
- Stable dose of maintenance medications for psychiatric conditions
- Clinically stable medical conditions

### Key exclusion criteria

- BPRS total score ≥50 at screening
- Significant suicidal ideation or behavior
- History of prolonged QT syndrome
- For participants with diagnosed schizophrenia or schizoaffective disorder
  - CDSS total score ≥10
  - PANSS total score ≥70
- For participants with diagnosed mood disorder
  - YMRS total score >10
  - MADRS [SIGMA] total score >13
  - Hospitalization for BD or MDD within 6 months before screening
  - Mood episodes<sup>†</sup> within 2 months before screening
  - History of rapid or ultra-rapid cycling

BD, bipolar disorder; BPRS, Brief Psychiatric Rating Scale; CDSS, Calgary Depression Scale for Schizophrenia; MADRS [SIGMA], Montgomery-Asberg Depression Rating Scale using the Structured Interview Guide; MDD, major depressive disorder; PANSS, Positive and Negative Syndrome Scale; TD, tardive dyskinesia; YMRS, Young Mania Rating Scale.

<sup>\*</sup>Mood disorder primarily includes BDs and depressive disorders. †Including hypomania, mania, depressive, etc.

<sup>1.</sup> Hauser RA, et al. Am J Psychiatry. 2017;174(5):476-484. 2. Data on file. Neurocrine Biosciences, Inc.

### **KINECT 3: Baseline Characteristics**<sup>1,2</sup>

Characteristics (Safety Analysis Set)	РВО (n=76)	VBZ 40 mg (n=72)	VBZ 80 mg (n=79)
Age, mean years (SD)	57 (10.5)	55 (8.5)	56 (10.1)
Age at TD diagnosis, mean years (SD)	49 (10.7)	48 (10.5)	48 (12.5)
Male, n (%)	42 (55.3)	42 (58.3)	39 (49.4)
White, n (%)	43 (56.6)	41 (56.9)	44 (55.7)
Black, n (%)	29 (38.2)	26 (36.1)	32 (40.5)
Schizophrenia/schizoaffective disorder, n (%)	50 (65.8)	48 (66.7)	52 (65.8)
Mood disorder, n (%)*	26 (34.2)	24 (33.3)	27 (34.2)
BPRS score, mean (SD)	29.3 (7.0)	30.6 (7.6)	29.1 (6.6)
AIMS score, mean (SD)	9.9 (4.3)	9.7 (4.1)	10.4 (3.6)
Receiving concomitant antipsychotic medication, n (%)	63 (83)	66 (92)	65 (82)
Receiving concomitant anticholinergic medication, n (%)	22 (28.9)	30 (41.7)	32 (40.5)



AIMS, Abnormal Involuntary Movement Scale; BD, bipolar disorder; BPRS, Brief Psychiatric Rating Scale; PBO, placebo; SD, standard deviation; TD, tardive dyskinesia; VBZ, valbenazine. Data presented for safety analysis set.

\*Mood disorder primarily includes BDs and depressive disorders.

1. Hauser RA, et al. Am J Psychiatry. 2017;174(5):476-484. 2. Data on file. Neurocrine Biosciences, Inc.

AIMS CFB at Week 6

(Primary Efficacy Endpoint)

PBO

(n=76)

(n=70)


(n=79)

VBZ 40 mg

VBZ 80 mg

### 

### **KINECT 3: AIMS Results (ITT Population\*)**



Percentage of Participants Who Had ≥50% Improvement in AIMS CFB at Week 6

AIMS CFB Key 2° Endpoint: CGI-TD Score Psychiatric CFB

AIMS, Abnormal Involuntary Movement Scale; BL, baseline; CFB, change from baseline; CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; ITT, intent-to-treat; MMRM, mixed model repeated measure; NNT, number needed to treat; SEM, standard error of the mean.

\*Included all randomized participants who had ≥1 postrandomization AIMS value. †Least squares mean based on the MMRM model, which includes baseline AIMS dyskinesia total score value as a covariate, and treatment group, disease category, visit, treatment group by visit, and baseline by visit interaction as fixed effects, and participant as a random effect. ‡ Cohen's d (treatment effect size). Hauser RA, et al. Am J Psychiatry. 2017;174(5):476-484.

### 

### **KINECT 3: TEAEs (Safety Population)**

Event, %	Placebo (n=76)	Valbenazine 40 mg (n=72)	Valbenazine 80 mg (n=79)	Valbenazine, Both Dosage Groups (n=151)
Any event	43.4	40.3	50.6	45.7
Any event leading to discontinuation	5.3	5.6	6.3	6.0
Any serious event	3.9	5.6	7.6	6.6
Events by preferred term*				
Somnolence	3.9	5.6	5.1	5.3
Akathisia	1.3	4.2	2.5	3.3
Dry mouth	1.3	6.9	0.0	3.3
Suicidal ideation	5.3	4.2	1.3	2.6
Arthralgia	1.3	1.4	3.8	2.6
Headache	2.6	2.8	2.5	2.6
Vomiting	0.0	0.0	3.8	2.0
Dyskinesia	0.0	0.0	3.8	2.0
Anxiety	0.0	1.4	2.5	2.0
Insomnia	1.3	1.4	2.5	2.0
Fatigue	1.3	2.8	1.3	2.0
Urinary tract infection	3.9	4.2	0.0	2.0
Weight increase	0.0	1.4	2.5	2.0

- No observed changes in depression or suicidality safety scales
- No safety signals observed for clinical hematology, chemistry, or ECG

ECG, electrocardiogram; PBO, placebo; TEAE, treatment-emergent adverse event; VBZ, valbenazine. \*Reported in  $\geq$ 2% of participants in the VBZ total group (both dosage groups). Hauser RA, et al. *Am J Psychiatry*. 2017;174(5):476-484. TARDIVE DYSKINESIA

VALBENAZINE

KINECT 3

**KINECT 3 EXTENSION** 


KINECT 4

# KINECT 3 (NCT02274558): Double-blind Extension Period

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP

### **KINECT 3 Extension: Study Design**

42-week extension period of double-blind VBZ treatment






Ĩn

DBPC, double-blind placebo-controlled; TD, tardive dyskinesia; VBZ, valbenazine; VE, valbenazine extension.

\*All dosing started at 40 mg and increased to 80 mg after the first week. \*Participants and investigators were blinded to treatment arms. Central video reviewers were blinded to study arm and study visit sequence.

Factor SA, et al. J Clin Psychiatry. 2017;78(9):1344-1350.

### **KINECT 3 Extension: AIMS CFB**




AIMS, Abnormal Involuntary Movement Scale; CFB, change from baseline; DBPC, double-blind placebo-controlled; ITT, intent-to-treat; PBO, placebo; SEM, standard error of the mean; VBZ, valbenazine. Data presented for ITT analysis set.

Factor SA, et al. *J Clin Psychiatry*. 2017;78(9):1344-1350.

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP	

### KINECT 3 Extension: ≥50% AIMS Response\*



AIMS, Abnormal Involuntary Movement Scale; DBPC, double-blind placebo-controlled; PBO, placebo; VBZ, valbenazine; VE, valbenazine extension.


VE and drug-free follow-up periods: no significance testing between doses were performed.

\*AIMS response threshold: participants with ≥50% reduction in AIMS score. <sup>†</sup>*p*-value versus PBO at end of DBPC, based on a 2-sided Cochran-Mantel-Haenszel analysis. Factor SA, et al. *J Clin Psychiatry*. 2017;78(9):1344-1350.

### 

### **KINECT 3 Extension: CGI-TD and PGIC**

Overall, both clinicians and patients reported sustained improvements in TD by the end of valbenazine treatment (48 weeks)



#### Mean CGI-TD and PGIC Scores at Week 48

<sup>†</sup>Total change in condition rated as 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; PGIC, Patient Global Impression of Change; TD, tardive dyskinesia; VBZ, valbenazine. Factor SA, et al. *J Clin Psychiatry*. 2017;78(9):1344-1350.

### **KINECT 3 Extension: Adverse Events**<sup>1,2</sup>

AEs Reported in ≥4%	Valbenazine 40 mg (n=97)	Valbenazine 80 mg (n=101)
Any AE, %	62	76
Diarrhea	3	8
Dizziness	4	7
Headache	7	7
Urinary tract infection	6	7
Suicidal ideation	5	5
Bronchitis	2	4
Constipation	4	4
Cough	3	4
Nasal congestion	1	4
Nausea	3	4
Somnolence	3	4
Weight increase	1	4
Anxiety	4	3
Decreased appetite	4	3
Vomiting	4	3
Weight decreased	4	3
Depression	6	2




#### AE, adverse event; VBZ, valbenazine.

1. Factor SA, et al. J Clin Psychiatry. 2017;78(9):1344-1350. 2. Data on file. Neurocrine Biosciences, Inc.

**KINECT 3 EXTENSION** 

### **KINECT 3 Patient Cases**

Case 1: 54-Year-Old White Female With Mood Disorder (Bipolar 1)



#### Case 2: 44-Year-Old Hispanic Female With Mood Disorder (Major Depression)



TARDIVE DYSKINESIA

VALBENAZINE

KINECT 3

**KINECT 3 EXTENSION** 

**KINECT 4** 


BACKUP

# KINECT 4 (NCT02405091): Long-term, Open-label Study

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP

### **KINECT 4: Study Design**

Open-label study to evaluate safety and tolerability of once-daily VBZ



40 mg was tolerated

CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; TD, tardive dyskinesia; VBZ, valbenazine. Postbaseline study visits during open-label treatment were at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.

40 mg: never had a dose increase to 80 mg; 80 mg: received 40 mg and increased to 80 mg, without a subsequent dose reduction;  $80 \rightarrow 40$  mg: dose reduction from 80 to 40 mg.

Patients who received 80 mg in the KINECT 4 study followed a different dosing schedule than those in the KINECT 3 pivotal study. In KINECT 3, patients had a dose increase from 40 to 80 mg after Week 1. In KINECT 4, patients had a dose increase from 40 to 80 mg after Week 4. The impact of this on long-term effectiveness is not known.

\*Including CGI-TD scores ranging from 3 ("minimally improved") to 7 ("very much worse"). Marder SR, et al. ACNP 2017; Palm Springs, CA. KINECT 3 EXTENSION

## **KINECT 4: Eligibility Criteria**



- DSM diagnosis of drug-induced TD for >3 months before screening
- DSM diagnosis of schizophrenia/schizoaffective disorder or mood disorder
- Moderate or severe TD as qualitatively assessed by a blinded, external reviewer based on AIMS videos

# - Key exclusion criteria

- Comorbid movement disorder that was more prominent than TD
- Significant risk for suicidal or violent behavior


AIMS, Abnormal Involuntary Movement Scale; DSM, *Diagnostic and Statistical Manual of Mental Disorders*; TD, tardive dyskinesia. Marder SR, et al. ACNP Congress 2017; Palm Springs, CA.

### **KINECT 4: Assessments**

AIMS total score (sum of items 1–7) by blinded central video raters

Efficacy

- Scored at baseline, Weeks 8 and 52
- AIMS total score by site investigators (exploratory measure)
  - Scored at baseline, Weeks 8, 12, 24, 36, 48, and 52
- CGI-TD
- PGIC



AIMS, Abnormal Involuntary Movement Scale; CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; PGIC, Patient Global Impression of Change; TEAE, treatment-emergent adverse event. Marder SR, et al. J Clin Psychopharmacol. 2019;39(6):620-627.

### **KINECT 4: Baseline Characteristics**<sup>1,2</sup>


	Valbenazine 40 mg	Valbenazine 80 mg	All Participants
Characteristic	(n=45)	(n=107)	(n=163)
Age, mean (SD), years	56.8 (11.2)	57.8 (9.0)	57.4 (9.6)
Male, n (%)	21 (46.7)	59 (55.1)	86 (52.8)
Race, n (%)			
White/Caucasian	26 (57.8)	74 (69.2)	110 (67.5)
Black/African American	16 (35.6)	31 (29.0)	48 (29.4)
Other	3 (6.7)	2 (1.9)	5 (3.1)
BMI, mean (SD), kg/m <sup>2</sup>	27.8 (6.0)	29.0 (5.4)	28.5 (5.5)
Age at TD diagnosis, mean (SD), years	47.8 (11.9)	49.2 (11.4)	48.4 (11.9)
Primary psychiatric diagnosis, n (%)			
Schizophrenia/schizoaffective disorder	37 (82.2)	76 (71.0)	119 (73.0)
Mood disorder	8 (17.8)	31 (29.0)	44 (27.0)
Lifetime suicidal ideation or behavior, n (%) <sup>†</sup>	17 (37.8)	48 (44.9)	69 (42.3)
AIMS scores, mean (SD)			
Total score by central raters <sup>‡</sup>	10.2 (3.9)	10.0 (3.9)	10.0 (3.8)
Total score by site raters <sup>‡</sup>	14.2 (5.5)	15.0 (4.5)	14.6 (4.8)
Item 8 score (severity of abnormal movements overall) by site raters ${}^{\$}$	3.1 (0.5)	3.2 (0.5)	3.2 (0.6)
Item 9 score (incapacitation due to abnormal movements) by site raters§	2.4 (0.9)	2.6 (0.8)	2.5 (0.9)
Item 10 score (participant's awareness of abnormal movements) by site raters $\$$	2.8 (0.9)	2.7 (0.7)	2.7 (0.8)
Receiving concomitant antipsychotic medication, n (%)	40 (88.9)	95 (88.8)	144 (88.3)
Receiving concomitant anticholinergic medication, n (%)	10 (22.2)	33 (30.8)	44 (27.0)

AIMS, Abnormal Involuntary Movement Scale; BMI, body mass index; C-SSRS, Columbia-Suicide Severity Rating Scale; SD, standard deviation; TD, tardive dyskinesia.

\*Includes 11 participants who had a dose reduction from 80 mg/day to 40 mg/day after Week 4. <sup>†</sup>Based on the C-SSRS. <sup>‡</sup>Sum of AIMS items 1–7. <sup>§</sup>AIMS items were scored on a scale from 0 ("none") to 4 ("severe").

1. Marder SR, et al. J Clin Psychopharmacol. 2019;39(6):620-627. 2. Data on file. Neurocrine Biosciences, Inc.

### **KINECT 4: AIMS Mean Score CFB by Visit**



AIMS, Abnormal Involuntary Movement Scale; BL; baseline; CFB, change from baseline; SEM, standard error of the mean; VBZ, valbenazine.

40 mg: never had a dose increase to 80 mg; 80 mg: received 40 mg and increased to 80 mg, without a subsequent dose reduction; 80-40 mg: dose reduction from 80 to 40 mg.

\*Patients who received VBZ 80 mg in the KINECT 4 study followed a different dosing schedule than those in the KINECT 3 pivotal study (dose increase from 40 to 80 mg after Week 4 in KINECT 4 versus after Week 1 in KINECT 3). The impact of this on long-term effectiveness is not known.

Marder SR, et al. J Clin Psychopharmacol. 2019;39(6):620-627.

### **KINECT 4:** Response and Shift Analyses, Response Thresholds for AIMS Total Score

#### 95.0 ≥10% 97.6 95.0 ≥20% 96.4 90.0 ≥30% 95.2 90.0 ≥40% 92.8 90.0 ≥50% 85.5 90.0 ≥60% 68.7 65.0 ≥70% 49.4 30.0 ≥80% 41.0 20.0 ≥90% 21.7 VBZ 40 mg (n=20) 10.0 ■ VBZ 80 mg (n=83) 100% 9.6

Percentage of Participants Meeting Response Threshold<sup>a</sup>


AIMS, Abnormal Involuntary Movement Scale; VBZ, valbenazine. <sup>a</sup>Includes 9 participants with available data who had a dose reduction from 80 to 40 mg. Marder SR, et al. NEI 2019; CO Springs, CO. TARDIVE DYSKINESIA

KINECT 3

BACKUP

### **KINECT 4: CGI-TD and PGIC**

Clinician- and patient-rated measures indicated sustained improvements in TD with long-term (up to 48 weeks) valbenazine treatment



#### Mean CGI-TD and PGIC Scores at Week 48

<sup>†</sup>Total change in condition rated as 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. Data not shown for 11 participants who had a dose reduction from 80 mg/day to 40 mg/day after week 4.

CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; PGIC, Patient Global Impression of Change; TD, tardive dyskinesia; VBZ, valbenazine.

Marder SR, et al. ACNP 2017; Palm Springs, CA.

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP	

### **KINECT 4: Safety and Tolerability**

	TEAEs*				
	VBZ 40 mg (n=35)	VBZ 80 mg (n=107)	VBZ 80→40 mg (n=11)	All Participants (n=153)	
Summary, n (%)					
Any TEAE	22 (62.9)	66 (61.7)	11 (100.0)	99 (64.7)	
Any serious AE	3 (8.6)	17 (15.9)	1 (9.1)	21 (13.7)	
Any TEAE leading to discontinuation	7 (20.0)	11 (10.3)	0 (0.0)	18 (11.8)	
TEAEs reported in ≥5% of al	I participants by preferred term,	n (%)			
Urinary tract infection	3 (8.6)	9 (8.4)	1 (9.1)	13 (8.5)	
Headache	2 (5.7)	6 (5.6)	0 (0.0)	8 (5.2)	

• CFB in vital signs, ECG, and laboratory test were generally small and not clinically significant

• VBZ was generally well-tolerated, and no unexpected safety signals were found

AE, adverse event; CFB, change from baseline; ECG, electrocardiogram; TEAE, treatment-emergent adverse event; VBZ, valbenazine.

40 mg: never had a dose increase to 80 mg; 80 mg: received 40 mg and increased to 80 mg, without a subsequent dose reduction; 80-40 mg: dose reduction from 80 to 40 mg.

1 death was due to breast cancer, which was determined not to be related to the study drug.

\*In participants who received  $\geq$ 1 dose of study drug, reported after Weeks 4 to 48.

Marder SR, et al. J Clin Psychopharmacol. 2019;39(6):620-627.

KINECT 3

**KINECT 3 EXTENSION** 

KINECT 4

BACKUP

#### **Valbenazine in Tardive Dyskinesia**

TD is defined as abnormal, involuntary movements of the tongue, jaw, trunk, or extremities that develop in association with medications that block post-synaptic dopamine receptors<sup>1</sup>



A leading theory of the mechanism of TD is the upregulation and subsequent hypersensitivity of brain dopamine D2 receptors following prolonged exposure to DRBAs<sup>2</sup>



The 2020 APA Schizophrenia Guidelines recommends reversible VMAT2 inhibitors in patients with moderate to severe or disabling TD<sup>3</sup>

VMAT2 inhibitors can also be considered for patients with mild TD based on factors such as patient preference, associated impairment, or effect on psychosocial functioning



Valbenazine is a VMAT2 inhibitor FDA-approved as safe and effective for the treatment of adults with tardive dyskinesia<sup>4</sup>

TD, tardive dyskinesia; DRBA, dopamine receptor blocking agent; VMAT2, vesicular monoamine transporter 2; APA, American Psychiatric Association.

1. American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders*. Fifth Edition. American Psychiatric Association: Washington, DC; 2013. 2. Klawans H, et al. *Acta Neurol Scand*. 1970;46:409-441. 3. APA Practice Guideline for Treatment of Patients with Schizophrenia. Accessed on November 17, 2022. <u>https://www.psychiatrists/practice/clinical-practice-guidelines</u>. 4. INGREZZA<sup>®</sup> (valbenazine) [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.

# FREE EDUCATIONAL RESOURCES on Tardive Dyskinesia and Other Drug-Induced Movement Disorders

These educational resources were sponsored and developed by Neurocrine Biosciences, Inc.

### **Discover TD**<sup>®</sup>

#### Discover TD° is an

interactive experience designed to inform health care providers about tardive dyskinesia and other drug-induced movement disorders. By interacting with hypothetical virtual

patients, you can diagnose and determine an appropriate management plan.<sup>a</sup>

<sup>a</sup>For educational purposes only. Should not be interpreted as medical advice for any particular patient. Individual results may vary.

> Experience Discover TD°

mind-td.com/discover-td



#### DIMD, drug-induced movement disorder; DRBA, dopamine receptor-blocking agent; TD, tardive dyskinesia.

©2024 Neurocrine Biosciences, Inc. All Rights Reserved. MED-CON-TD-US-0101



#### **DIMD Course**

The **DIMD Course** is a free, virtual learning resource for health care providers that delves into



various clinical aspects of the most common DRBA-induced movement disorders.

#### Neurocrine Medical Website

The **Neurocrine Medical Website** houses a variety of resources, such as educational podcasts

and videos, to assist healthcare providers in the recognition and appropriate differentiation of DRBA-induced movement disorders.

Visit the Neurocrine Medical Website neurocrinemedical.com





Join the DIMD Course dimdcourse.getlearnworlds.com



## www.neurocrinemedical.com

**Neurocrine Medical Affairs** 







# Appendix

#### Moderate Cervical and Jaw

Open Mouth and Tongue


Neck, Shoulder, and Hands (Standing and Walking)  $\times$ 







Patients have consented to Neurocrine's use of this video and their protected health information.




# Mild Jaw and Hand


#### Activation With Hand Movement

# Increased Blinking and Jaw Activation


 $\times$ 



#### Leg and Shoulder Dyskinesia



Facial Grimacing and Head Nodding  $\times$ 



Patients have consented to Neurocrine's use of this video and their protected health information.




#### **Tardive Dyskinesia: Mechanism of Disease Video**



TD, tardive dyskinesia.



### **Trend in Antipsychotic Prescribing**



- >4-fold increase in antipsychotic use >25 years<sup>1</sup>
- Use of SGAs in new conditions and client populations has grown over the past 3 decades<sup>1,2</sup>

#### FGA, first-generation antipsychotic; SGA, second-generation antipsychotic.

1. Data on file (VBZ-TD-0014). Neurocrine Biosciences, Inc. 2. Alexander GC, et al. Pharmacoepidemiol Drug Saf. 2011;20(2)177-184.



### **Factors Associated With Increased Risk for TD**

#### **Risk Factors for TD**


Treatment Factors	Patient Factors	
Cumulative exposure to antipsychotics <sup>1</sup>	Increased age <sup>1</sup>	
Treatment with anticholinergics <sup>1</sup>	Substance abuse <sup>1</sup>	
History of EPS <sup>1</sup>	Diagnosis of mood disorder <sup>3,4</sup>	
Potency of DRBA <sup>2</sup>	Postmenopausal women <sup>5</sup>	
Neuroleptic withdrawal-emergent dyskinesia6		

DRBA, dopamine receptor-blocking agent; EPS, extrapyramidal symptoms; TD, tardive dyskinesia.

1. Miller DD, et al. Schizophr Res. 2005;80:33-43. 2. Divac N. Biomed Res Int. 2014;2014:656370. 3. Jeste DV, et al. Schizophr Bull. 1993;19:303-315. 4. Mukherjee S. Arch Gen Psychiatry. 1986;43:342-346. 5. Seeman MV. Compr Psychiatry. 1983;24(2):125-128. 6. Solmi M, et al. J Neurol Sci. 2018;389:21-27.


# Scoring AIMS (cont'd)


Each total AIMS score can represent a range of clinical presentations





#### AIMS, Abnormal Involuntary Movement Scale.

Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76-338). National Institute of Mental Health, Psychopharmacology Research Branch; 1976:534-537.










## **Screen All Patients Taking Antipsychotics at Each Visit**

#### Due to the serious and persistent nature of TD, accurate diagnosis is critical<sup>1</sup>

- Accurate diagnosis may be challenging due to the subtle and often fluctuating symptoms, especially in an older population with various comorbidities
- Misdiagnosis and inappropriate treatment selection can worsen TD<sup>2</sup>
- TD assessments should include regular clinical assessments and periodic assessments using a structured instrument (e.g., AIMS)<sup>1,2</sup>

#### Clinical Assessments<sup>1,2</sup>




#### CMS, Centers for Medicare & Medicaid Services; TD, tardive dyskinesia; AIMS, Abnormal Involuntary Movement Scale.

1. American Psychiatric Association. Clinical practice guidelines for treatment of patients with schizophrenia. Accessed on March 8, 2023. https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841. 2. Caroff SN, et al. *J Clin Psychiatry*. 2020;81(2):19cs12983. 3. CMS. State operations manual. Appendix PP – guidance to surveyors for long term care facilities. Revised February 3, 2023. Accessed March 31, 2023. https://www.cms.gov/medicare/provider-enrollment-and-certification/guidanceforlawsandregulations/downloads/appendix-pp-state-operations-manual.pdf.



#### **2018 Systematic Review: Practical Treatment Algorithma**



GPi DBS, pallidus interna deep brain stimulation; TD, tardive dyskinesia; VBZ, valbenazine; VMAT2, vesicular monoamine transporter type 2.

aAdapted for the management of troublesome TD in patients receiving an approved antipsychotic treatment as indicated. Assessment of TD is necessary before treatment.

<sup>b</sup>Consider tetrabenazine if the new-generation VMAT2 inhibitors are unavailable.


Bhidayasiri R, et al. J Neurol Sci. 2018;389:67-75.



#### **Valbenazine Mechanism of Action Video**




## MIDD Modeling & Simulation for Valbenazine 60 mg: Methodology





MIDD, model-informed drug development; PK, pharmacokinetic; DBPC, double-blind placebo-control; TD, tardive dyskinesia; PBO, placebo. Data on File. Neurocrine Biosciences, Inc.

### MIDD Modeling & Simulation for Valbenazine 60 mg: AIMS Results



Predicted population mean CFB in AIMS at Week 6 for valbenazine 60 mg is

> **—2.69** (95% CI: –3.30, –2.13)

The simulated dataset was designed to replicate the KINECT 3 study methodology, dose regimen, and covariate distributions



AIMS, Abnormal Involuntary Movement Scale; CFB, change from baseline; CI, confidence interval; MIDD, model-informed drug development; AIMS, Abnormal Involuntary Movement Scale. INGREZZA® (valbenazine). Package insert. Neurocrine Biosciences, Inc., 2021.



### **KINECT 3 & MIDD Modeling & Simulation: AIMS Results**



AIMS, Abnormal Involuntary Movement Scale; CFB, change from baseline; CI, confidence interval; ITT, intent-to-treat; LS, least squares; MIDD, model-informed drug development; MMRM, mixed model repeated measure; SEM, standard error of the mean.

\*ITT included all randomized participants who had ≥1 postrandomization AIMS value.

<sup>†</sup>LS mean based on the MMRM model, which includes baseline AIMS dyskinesia total score value as a covariate, and treatment group, disease category, visit, treatment group by visit, and baseline by visit interaction as fixed effects, and participant as a random effect. <sup>‡</sup>Nominal p-value, statistical analysis plan-specified hierarchical analysis precluded testing 40-mg result for significance. <sup>§</sup>Cohen's d (treatment effect size).

1. Hauser RA, et al. Am J Psych. 2017;174(5):476-484. 2. INGREZZA® (valbenazine). Package insert. Neurocrine Biosciences, Inc., 2021.



### **Valbenazine: Drug Interactions**

**Clinically Significant Drug Interactions with INGREZZA and INGREZZA SPRINKLE** 

MAOIs			
Clinical impact	Concomitant use of INGREZZA or INGREZZA SPRINKLE with MAOIs may increase the concentration of monoamine neurotransmitters in synapses, potentially leading to increased risk of adverse reactions such as serotonin syndrome, or attenuated treatment effect of INGREZZA or INGREZZA SPRINKLE.		
Prevention or management	Avoid concomitant use of INGREZZA or INGREZZA SPRINKLE with MAOIs, or within 14 days of discontinuing therapy with an MAOI.		
Examples	Isocarboxazid, phenelzine, selegiline		
Strong CYP3A4 Inhibitors			
Clinical impact	Concomitant use of INGREZZA or INGREZZA SPRINKLE with strong CYP3A4 inhibitors increased the exposure (Cmax and AUC) to valbenazine and its active metabolite compared with the use of INGREZZA or INGREZZA SPRINKLE alone. Increased exposure of valbenazine and its active metabolite may increase the risk of exposure-related adverse reactions.		
Prevention or management	Reduce INGREZZA or INGREZZA SPRINKLE dose when INGREZZA or INGREZZA SPRINKLE is coadministered with a strong CYP3A4 inhibitor.		
Examples	Itraconazole, ketoconazole, clarithromycin		

AUC, area under the curve; C<sub>max</sub>, maximum observed concentration; CYP, cytochrome P450; MAOI, monoamine oxidase inhibitor. INGREZZA® (valbenazine). Package insert. Neurocrine Biosciences, Inc., San Diego, CA.



### Valbenazine: Drug Interactions (cont'd)

#### **Clinically Significant Drug Interactions with INGREZZA and INGREZZA SPRINKLE**

Strong CYP2D6 Inhibitors		
Clinical impact	Concomitant use of INGREZZA or INGREZZA SPRINKLE with strong CYP2D6 inhibitors increased the exposure (Cmax and AUC) to valbenazine's active metabolite compared with the use of INGREZZA or INGREZZA SPRINKLE alone. Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions.	
Prevention or management	Reduce INGREZZA or INGREZZA SPRINKLE dose when INGREZZA or INGREZZA SPRINKLE is coadministered with a strong CYP2D6 inhibitor.	
Examples	Paroxetine, fluoxetine, quinidine	
Strong CYP3A4 Inducers		
Clinical impact	Concomitant use of INGREZZA or INGREZZA SPRINKLE with a strong CYP3A4 inducer decreased the exposure of valbenazine and its active metabolite compared to the use of INGREZZA or INGREZZA SPRINKLE alone. Reduced exposure of valbenazine and its active metabolite may reduce efficacy.	
Prevention or management	Concomitant use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE is not recommended.	
Examples	Rifampin, carbamazepine, phenytoin, St. John's wort*	
Digoxin		
Clinical impact	Concomitant use of INGREZZA or INGREZZA SPRINKLE with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp)	
Prevention or management	Digoxin concentrations should be monitored when co-administering INGREZZA or INGREZZA SPRINKLE with digoxin. Increased digoxin exposure may increase the risk of exposure-related adverse reactions. Dosage adjustment of digoxin may be necessary.	

AUC, area under the curve;  $C_{max}$ , maximum observed concentration; CYP, cytochrome P450; P-gp, P-glycoprotein.

\*The induction potency of St. John's wort may vary widely based on preparation.

INGREZZA® (valbenazine). Package insert. Neurocrine Biosciences, Inc., 2021.



### **KINECT 3: Concomitant Medication Use (Safety Population)**

Medications*	Placebo (n=76)	VBZ 40 mg (n=72)	VBZ 80 mg (n=79)
Typical antipsychotics, n (%)			
Haloperidol	4 (5.3)	13 (18.1)	10 (12.7)
Atypical antipsychotics, n (%)			
Quetiapine	18 (23.7)	23 (31.9)	14 (17.7)
Risperidone	14 (18.4)	11 (15.3)	16 (20.3)
Aripiprazole	10 (13.2)	8 (11.1)	10 (12.7)
Olanzapine	11 (14.5)	8 (11.1)	8 (10.1)
Ziprasidone	1 (1.3)	4 (5.6)	9 (11.4)
Antidepressants, n (%)			
Trazodone	10 (13.2)	17 (23.6)	16 (20.3)
Citalopram	10 (13.2)	10 (13.9)	10 (12.7)
Sertraline	13 (17.1)	9 (12.5)	8 (10.1)
Fluoxetine	10 (13.2)	7 (9.7)	3 (3.8)
Mirtazapine	6 (7.9)	8 (11.1)	5 (6.3)
Anticholinergics, n (%)			
Benztropine	19 (25.0)	29 (40.3)	26 (32.9)


\*Taken by  $\geq$ 10% of participants in any treatment group.

VBZ, valbenazine.

Hauser RA, et al. Am J Psychiatry. 2017;174(5):476-484.

# KINECT 3: AIMS CFB by Study Visit (ITT Population<sup>\*</sup>)<sup>1,2</sup>


Some participants began to see a response as early as Week 2



AIMS, Abnormal Involuntary Movement Scale; CFB, change from baseline; ITT, intent-to-treat; PBO, placebo; VBZ, valbenazine.

\*ITT: Included all randomized participants who had ≥1 postrandomization AIMS value. <sup>†</sup>Dose that was statistically significantly different from placebo after adjusting for multiplicity. Hauser RA, et al. Am J Psychiatry. 2017;174(5):476-484.

# KINECT 3: Key Secondary Endpoint CGI-TD Score (ITT Population\*)




#### **CGI-TD Mean Score at Week 6**

CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; ITT, intent-to-treat; VBZ, valbenazine.

\*ITT: Included all randomized participants who had ≥1 postrandomization AIMS value. †Total change in condition rated as 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.

Hauser RA, et al. Am J Psychiatry. 2017;174(5):476-484.

### KINECT 3 Psychiatric Rating Scales: CFB to Week 6




CDSS, Calgary Depression Scale for Schizophrenia; CFB, change from baseline; MADRS, Montgomery-Asberg Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; VBZ, valbenazine; YMRS, Young Mania Rating Scale.

For the PANSS and CDSS: placebo n=50, VBZ 40 mg n=48, VBZ 80 mg n=52; MADRS and YMRS: placebo n=26, VBZ 40 mg n=24, VBZ 80 mg n=27. Factor SA, et al. *MDS* 2016.

#### 64 Appendix




### **KINECT 3 Extension: Participant Disposition**



AE, adverse event; DBPC, double-blind placebo-controlled; SAE, serious adverse event; TEAE, treatment-emergent adverse event; VE, valbenazine extension. Grigoriadis D, et al. ACNP 2016.



#### **KINECT 3 Extension: AIMS CFB for VBZ Groups**




AIMS, Abnormal Involuntary Movement Scale; DBPC, double-blind placebo-controlled; ITT, intent-to-treat; SEM, standard error of the mean; PBO, placebo; VBZ, valbenazine.

#### Data presented for ITT analysis set.

Factor SA, et al. J Clin Psychiatry. 2017;78(9):1344-1350.



#### **KINECT 3 Extension: AIMS CFB for Rerandomized Groups**




AIMS, Abnormal Involuntary Movement Scale; DBPC, double-blind placebo-controlled; ITT, intent-to-treat; SEM, standard error of the mean; PBO, placebo; VBZ, valbenazine.

#### Data presented for ITT analysis set.

Factor SA, et al. J Clin Psychiatry. 2017;78(9):1344-1350.




#### **KINECT 3 Extension: CGI-TD Scores**



CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; DBPC, double-blind placebo-controlled; PBO, placebo; VBZ, valbenazine; VE, valbenazine extension. At end of DBPC: no statistical difference between VBZ (80 or 40 mg) and PBO; based on least squares mean scores using a mixed-effects model for repeated measures. VE and drug-free follow-up periods: results based on arithmetic mean scores with no imputation of missing values or significance testing between dose groups. \*Total change in condition rated as 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. Factor SA, et al. *J Clin Psychiatry*. 2017;78(9):1344-1350.



#### **KINECT 3 Extension: CGI-TD Response\***



CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; DBPC, double-blind placebo-controlled; VBZ, valbenazine; VE, valbenazine extension.

At end of DBPC: no statistical difference between VBZ (80 or 40 mg) and PBO, based on a 2-sided Cochran-Mantel-Haenszel analysis.


VE and drug-free follow-up periods: no significance testing between doses were performed.

\*CGI-TD response: participants with CGI-TD rating of 1 (very much improved) or 2 (much improved).

Factor SA, et al. J Clin Psychiatry. 2017;78(9):1344-1350.



#### **KINECT 3 Extension: PGIC Response\***



\*PGIC response: participants with CGI-TD rating of 1 (very much improved) or 2 (much improved).

At end of DBPC: no statistical difference between valbenazine (80 or 40 mg) and placebo, based on a 2-sided Cochran-Mantel-Haenszel analysis.

VE and drug-free follow-up periods: no significance testing between doses were performed.

DBPC, double-blind placebo-controlled; PGIC, Patient Global Impression of Change; VBZ, valbenazine; VE, valbenazine extension.

Factor SA, et al. J Clin Psychiatry. 2017;78(9):1344-1350.

## **AEs Leading to Discontinuation**



#### 6-week controlled and long-term extension period from KINECT 3

- In the placebo-controlled period, 5% of the placebo group, 6% of the valbenazine 40-mg group, and 6% of the valbenazine 80-mg group experienced AEs leading to discontinuation
  - Placebo (all n=1): Tourette syndrome, nausea, mental status change, schizoaffective disorder
  - Valbenazine 40 mg (all n=1): body tinea, akathisia, anxiety, bipolar disorder, hostility, mental status change
  - Valbenazine 80 mg (all n=1): acute hepatitis, jaundice, schizoaffective disorder, suicidal ideation, suicide attempt
- In the extension treatment period, 13% of the valbenazine 40-mg group and 18% of the valbenazine 80-mg group experienced AEs leading to discontinuation
  - Valbenazine 40 mg (all n=1 unless noted): fatigue, increased A1C, decreased hemoglobin, syncope, TIA, tremor, mental status change, psychotic disorder, schizophrenia, trance, hematuria, acute renal failure, rash, hospitalization for social circumstances, suicidal ideation (n=2)
  - Valbenazine 80 mg (all n=1 unless noted): constipation, hypersalivation, fatigue, gait disturbance, peripheral edema, hepatic failure, auto accident, decreased appetite, diabetes mellitus, hyperkalemia, metabolic acidosis, osteoarthritis, attention disturbance, TIA, tremor, suicidal behavior, suicidal ideation, suicide attempt, pleural effusion, DVT, asthenia (n=2), somnolence (n=3)

# Case 1: 54-year-old White Female With Mood Disorder (Bipolar 1)

Baseline AIMS score: 20


Age at TD diagnosis: 44

**Comorbidities:** 

- Hypothyroid
- Generalized anxiety disorder
- Hypercholesterolemia

Relevant concomitant medications at baseline:

- Lithium
- Wellbutrin (bupropion)
- Artane (trihexyphenidyl)
- Klonopin (clonazepam)



Continue



# Case 1: 54-year-old White Female With Mood Disorder (Bipolar 1)

Randomized to receive VBZ 80 mg:

• Week 6 AIMS score of 7




Continue

AIMS, Abnormal Involuntary Movement Scale; VBZ, valbenazine. Hauser RA, et al. *Am J Psychiatry*. 2017;174(5):476-484. Data on file. Neurocrine Biosciences, Inc.

# Case 1: 54-year-old White Female With Mood Disorder (Bipolar 1)

Remains on VBZ 80 mg:

• Week 48 AIMS score of 5



Continue 🔿

AIMS, Abnormal Involuntary Movement Scale; VBZ, valbenazine. Hauser RA, et al. *Am J Psychiatry*. 2017;174(5):476-484. Data on file. Neurocrine Biosciences, Inc.



# Case 1: 54-year-old White Female With Mood Disorder (Bipolar 1)

4 weeks after treatment discontinuation

Week 52 AIMS score of 17



AIMS, Abnormal Involuntary Movement Scale. Hauser RA, et al. *Am J Psychiatry*. 2017;174(5):476-484. Data on file. Neurocrine Biosciences, Inc.



**Baseline AIMS score: 13** 

Age at TD diagnosis: unknown

**Comorbidities:** 

- Anxiety
- Insomnia

Relevant concomitant medications at baseline:

- Zoloft (sertraline)
- Klonopin (clonazepam)
- Cogentin (benztropine)
- Seroquel (quetiapine)




Continue



Randomized to PBO:

Week 6 AIMS score of 12



Continue

AIMS, Abnormal Involuntary Movement Scale; PBO, placebo. Hauser RA, et al. *Am J Psychiatry*. 2017;174(5):476-484. Data on file. Neurocrine Biosciences, Inc.



Rerandomized to receive VBZ 80 mg:

• Week 48 AIMS score of 5




Continue 🔿

AIMS, Abnormal Involuntary Movement Scale; VBZ, valbenazine. Hauser RA, et al. *Am J Psychiatry*. 2017;174(5):476-484. Data on file. Neurocrine Biosciences, Inc.




4 weeks after treatment discontinuation

Week 52 AIMS score of 14



AIMS, Abnormal Involuntary Movement Scale. Hauser RA, et al. *Am J Psychiatry*. 2017;174(5):476-484. Data on file. Neurocrine Biosciences, Inc.

## **KINECT 4: CGI-TD Mean Score by Visit**



CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; SEM, standard error of the mean.

40 mg: never had a dose increase to 80 mg; 80 mg: received 40 mg and increased to 80 mg, without a subsequent dose reduction; 80-40 mg: dose reduction from 80 to 40 mg.


\*Total change in condition rated as 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.

<sup>†</sup>Scores of the 40- and 80-mg $\rightarrow$ 40-mg groups were equal.

<sup>‡</sup>Scores of the 80- and 80-mg $\rightarrow$ 40-mg groups were equal.

Marder SR, et al. ACNP 2017; Palm Springs, CA.

## **KINECT 4: PGIC Mean Score by Visit**




PGIC, Patient Global Impression of Change; SEM, standard error of the mean; VBZ, valbenazine.

40 mg: never had a dose increase to 80 mg; 80 mg: received 40 mg and increased to 80 mg, without a subsequent dose reduction; 80-40 mg: dose reduction from 80 to 40 mg.

\*Total change in condition rated as 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. <sup>†</sup>Scores of the 40- and 80-mg→40-mg groups were equal. Marder SR, et al. ACNP 2017; Palm Springs, CA.

## **KINECT 4: CGI-TD Response\* Rate by Visit**





CGI-TD, Clinical Global Impression of Change-Tardive Dyskinesia; VBZ, valbenazine.


40 mg: never had a dose increase to 80 mg; 80 mg: received 40 mg and increased to 80 mg, without a subsequent dose reduction; 80 - 40 mg: dose reduction from 80 to 40 mg.

\*CGI-TD Score ≤2 ("Much Improved" or "Very Much Improved").

Marder SR, et al. ACNP Congress 2017; Palm Springs, CA.

## **KINECT 4: PGIC Response\* Rate by Visit**






PGIC, Patient Global Impression of Change; VBZ, valbenazine.

40 mg: never had a dose increase to 80 mg; 80 mg: received 40 mg and increased to 80 mg, without a subsequent dose reduction; 80-40 mg: dose reduction from 80 to 40 mg.

\*PGIC score ≤2 ("Much Improved" or "Very Much Improved").

Marder SR, et al. ACNP Congress 2017; Palm Springs, CA.



## **Backup Table of Contents**

Study 1506 (NCT02736955): Long-term, Open-label Rollover Phase 3b Study

у 😑

KINECT, KINECT 3, & KINECT 4: Pooled Long-term Safety Analysis



TARDIVE DYSKINESIA

VALBENAZINE

KINECT 3

**KINECT 3 EXTENSION** 

KINECT 4

 $\bigcirc$ 


# Study 1506 (NCT02736955): Long-term, Open-label Rollover Phase 3b Study

PROVIDED IN RESPONSE TO YOUR UNSOLICITED REQUEST FOR INFORMATION

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP	Ĺ

# Study 1506: Study Design

Open-label rollover study



TD, tardive dyskinesia; VBZ, valbenazine.

Patients who received VBZ 80 mg in the 1506 study followed a different dosing schedule than those in the KINECT 3 pivotal study. In KINECT 3, patients had a dose increase from 40 to 80 mg after Week 1. In KINECT 4 and 1506, patients had a dose increase from 40 to 80 mg after Week 4. The impact of this on long-term effectiveness is not known. Lindenmayer JP, et al. *ASCP 2018*; Miami, FL.


Ĺπ.

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP	
	-					

### **Study 1506: Assessments**

#### Efficacy

- All outcomes were analyzed descriptively in participants who received ≥1 dose of study drug and had ≥1 available postbaseline assessment
- Mean CGIS-TD scores were analyzed at every 12-week visit
- Percentages of participants with a CGIS-TD score of 1 ("normal, not at all ill") or 2 ("borderline ill") were also analyzed



**Safety** 

CGIS-TD, Clinical Global Impression of Severity-Tardive Dyskinesia; C-SSRS, Columbia-Suicide Severity Rating Scale; ECG, electrocardiogram; TEAE, treatment-emergent adverse event. Lindenmayer JP, et al. ASCP 2018; Miami, FL.

## Study 1506: Eligibility Criteria

### Key inclusion criteria

- Adults with neuroleptic-induced TD and a DSM psychiatric diagnosis (ie, schizophrenia, schizoaffective disorder, or mood disorder) who completed KINECT 3 or KINECT 4
- Psychiatrically stable before study entry (Brief Psychiatric Rating Scale score <50 at screening)

### Key exclusion criteria

- Active, clinically significant, and unstable medical condition
- Clinically significant parkinsonism per investigator judgment
- Significant risk for active suicidal ideation or suicidal behavior (C-SSRS) or violent behavior

C-SSRS, Columbia-Suicide Severity Rating Scale; DSM, *Diagnostic and Statistical Manual of Mental Disorders*; TD, tardive dyskinesia. Lindenmayer JP, et al. ASCP 2018; Miami, FL.

### **Study 1506: Baseline Characteristics**


#### Baseline characteristics were generally similar across treatment groups

	VBZ 40 mg	VBZ 80 mg	All Participants
	(n=35)	(n=117)	(n=160)*
Age, mean (SD), years	57.3 (8.9)	57.9 (8.8)	57.9 (8.8)
Male, n (%)	13 (37.1)	63 (53.8)	81 (50.6)
Race, n (%)			
White	21 (60.0)	86 (73.5)	111 (69.4)
Black	14 (40.0)	30 (25.6)	47 (29.4)
BMI, mean (SD), kg/m <sup>2</sup>	29.2 (5.5)	28.5 (5.5)	28.8 (5.5)
Primary psychiatric diagnosis, n (%)			
Schizophrenia/schizoaffective disorder	23 (65.7)	75 (64.1)	104 (65.0)
Mood disorder	12 (34.3)	42 (35.9)	56 (35.0)
Age at diagnosis, mean (SD), years			
Schizophrenia/schizoaffective disorder	27.1 (8.3)	28.7 (11.4)	28.2 (10.6)
Mood disorder	36.0 (12.0)	33.9 (13.3)	34.7 (13.2)
TD	48.3 (11.2)	48.4 (9.5)	48.0 (10.1)
BPRS total score, mean (SD)	27.3 (6.3)	26.1 (5.6)	26.6 (6.0)
CGIS-TD score, mean (SD)	3.9 (1.1)	3.9 (1.3)	3.9 (1.2)
C-SSRS lifetime at screening, n (%)			
Suicidal ideation	10 (28.6)	36 (30.8)	49 (30.6)
Suicidal behavior	10 (28.6)	32 (27.4)	44 (27.5)
		× /	× /

# The percentage of all participants taking ≥1 antipsychotic medication before the study (81.9%) was similar to the percentage during the study (82.5%)

\*Includes 8 participants who had a dose reduction from 80 to 40 mg after Week 4.

BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; CGIS-TD, Clinical Global Impression of Severity-Tardive Dyskinesia; C-SSRS, Columbia-Suicide Severity Rating Scale; SD, standard deviation; TD, tardive dyskinesia. Lindenmayer JP, et al. ASCP 2018; Miami, FL.




Few participants reached Week 60 (n=4) and none reached Week 72 (n=0) because valbenazine became commercially available before reaching those visits

Lindenmayer JP, et al. ASCP 2018; Miami, FL.


TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP

### Study 1506: Participants Completing Each Study Visit



Week

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP
Study 1506:	CGIS-TD	Mean Sco	ore by Visit		
	_				




CGIS-TD, Clinical Global Impression of Severity-Tardive Dyskinesia; VBZ, valbenazine.

Data not shown for participants who had a dose reduction from 80 to 40 mg (n=8) or any participant who completed the Week 60 visit (total n=4) due to the small sample sizes of these groups.

.\*Rated as 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill. †Baseline of rollover study.

Lindenmayer JP, et al. ASCP 2018; Miami, FL.

Ĺπ.`



CGIS-TD, Clinical Global Impression of Severity-Tardive Dyskinesia.

Data not shown for participants who had a dose reduction from 80 to 40 mg (n=8) or any participant who completed the Week 60 visit (total n=4) due to the small sample sizes of these groups.

#### \*Baseline of rollover study.

Lindenmayer JP, et al. ASCP 2018; Miami, FL.

TARDIVE DYSKINESIA

KINECT 3

**KINECT 3 EXTENSION** 

**KINECT 4** 


# Study 1506: Safety and Tolerability TEAEs


	Baseline to Week 4		Week 4 to End of Study	
	VBZ 40 mg (n=160)	VBZ 40 mg (n=32)	VBZ 80 mg (n=117)	All Participants (n=157)*
Summary, n (%)				
Any TEAE	15 (9.4)	14 (43.8)	56 (47.9)	77 (49.0)
Any serious TEAE	2 (1.3)	2 (6.3)	10 (8.5)	14 (8.9)
Any TEAE leading to discontinuation	2 (1.3)	0	6 (5.1)	7 (4.5)
Death	0	0	3 (2.6)	4 (2.5) <sup>†</sup>
TEAE by preferred term, n (%) <sup>‡</sup>				
Back pain	1 (0.6)	2 (6.3)	5 (4.3)	7 (4.5)
Urinary tract infection	0	1 (3.1)	6 (5.1)	7 (4.5)
Upper respiratory tract infection	0	1 (3.1)	5 (4.3)	6 (3.8)
Cough	1 (0.6)	1 (3.1)	3 (2.6)	5 (3.2)
Headache	0	1 (3.1)	4 (3.4)	5 (3.2)
Tremor	0	0	3 (2.6)	5 (3.2)
Fall	1 (0.6)	1 (3.1)	3 (2.6)	4 (2.5)
Nasopharyngitis	0	1 (3.1)	3 (2.6)	4 (2.5)
Somnolence	2 (1.3)	0	0	4 (2.5)
Suicidal ideation	0	1 (3.1)	3 (2.6)	4 (2.5)

TEAE, treatment-emergent adverse event; VBZ, valbenazine.

\*Includes 8 participants who had a dose reduction from 80 to 40 mg after Week 4. <sup>†</sup>Deaths occurred due to chronic obstructive pulmonary disease, sepsis syndrome, alcohol-induced coma, and hypertensive heart disease; none were judged as treatment-related. <sup>‡</sup>Reported in ≥2% of all participants from Week 4 to end of study.

Lindenmayer JP, et al. ASCP 2018; Miami, FL.





Change from baseline in vital signs, ECG parameters, and laboratory test values were generally small and not clinically meaningful

C-SSRS, Columbia-Suicide Severity Rating Scale; ECG, electrocardiogram. Lindenmayer JP, et al. ASCP 2018; Miami, FL. TARDIVE DYSKINESIA

VALBENAZINE

KINECT 3

**KINECT 3 EXTENSION** 


**KINECT 4** 

# KINECT, KINECT 3, & KINECT 4: Pooled Long-term Safety Analysis

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	<b>KINECT 3 EXTENSION</b>	KINECT 4	BACKUP	

### **Pooled LTE From 3 Studies**

VBZ-treated participants from KINECT, KINECT 3, and KINECT 4



#### Pooled LTE 40-mg group (3 studies):

- KINECT (50-mg group including those who initially received VBZ 100 mg for 2 weeks)
- KINECT 3 (40-mg group)
- KINECT 4 (40-mg group)

DBPC, double-blind placebo-controlled; LTE, long-term exposure; PBO, placebo VBZ, valbenazine. KINECT and KINECT 3 are completed. KINECT 4 is completed. Final data analysis is pending. \*KINECT, 100 mg for 2 weeks. Remington G, et al. ACNP 2016. Hollywood, FL.

#### Pooled LTE 80-mg group (2 studies):

- KINECT 3 (80 mg)
- KINECT 4 (80 mg)

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP

### KINECT, KINECT 3, & KINECT 4 Pooled Long-Term Safety Analysis: Baseline Characteristics (Safety Population)\*

	VBZ 40 mg (n=197)	VBZ 80 mg (n=230)	All Participants (n=427)
Age, mean years	56.2	56.9	56.6
<65 years, %	81.7	81.3	81.5
Male, %	59.4	52.2	55.5
White, %	56.3	65.7	61.4
Black, %	37.6	31.3	34.2
BMI			
Mean, kg/m <sup>2</sup>	28.1	28.4	28.2
25 to <30, %	33.5	35.7	34.7
≥30, %	36.5	35.7	36.1
Mean age at TD diagnosis, years	48.6	48.2	48.4
Psychiatric diagnosis and history, %			
Current schizophrenia/schizoaffective disorder	76.6	67.4	71.7
Current mood disorder	23.4	32.6	28.3
Lifetime history of suicidality <sup>†</sup>	39.1	40.4	39.8
Concomitant use of antipsychotics, %			
Any concomitant antipsychotic	88.3	83.0	85.5
Atypical only	71.6	68.3	69.8
Typical only or both	16.8	14.8	15.7
Psychiatric scales, mean			
PANSS total <sup>‡</sup>	57.2	49.8	53.5
PANSS positive symptoms <sup>‡</sup>	13.4	11.5	12.4
PANSS negative symptoms <sup>‡</sup>	15.4	13.5	14.5
PANSS general psychopathology <sup>‡</sup>	28.4	24.8	26.6
CDSS total <sup>‡</sup>	2.4	1.9	2.1
MADRS total <sup>§</sup>	6.2	5.5	5.7
YMRS total <sup>§</sup>	2.6	2.5	2.5


BMI, body mass index; CDSS, Calgary Depression Scale for Schizophrenia; C-SSRS, Columbia-Suicide Severity Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; TD, tardive dyskinesia; VBZ, valbenazine; YMRS, Young Mania Rating Scale.

\*As of 12/5/2016, baseline data not available for 3 participants. †Lifetime history of suicidality was defined as endorsement of any C-SSRS category for suicidal ideation (category 1–5) or suicidal behavior (category 6–10). ‡PANSS and CDSS were administered only to participants with schizophrenia/schizoaffective disorder (40 mg, n=154; 80 mg, n=155). §YMRS and MADRS were administered only to participants with mood disorder (40 mg, n=46; 80 mg, n=75). Remington G, et al. ACNP 2016; Hollywood, FL.

ſп

TARDIVE DYSKINESIA	VALBENAZINE	KINECT 3	KINECT 3 EXTENSION	KINECT 4	BACKUP	

### KINECT, KINECT 3, & KINECT 4 Pooled Long-term Safety Analysis: Mean Changes in Psychiatric Scales Scores



CDSS, Calgary Depression Scale for Schizophrenia; CFB, change from baseline; MADRS, Montgomery-Asberg Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; SEM, standard error of the mean; VBZ, valbenazine; YMRS, Young Mania Rating Scale.

PANSS and CDSS were administered only to participants with schizophrenia/schizoaffective disorder (40 mg, n=154; 80 mg, n=155). YMRS and MADRS were administered only to participants with mood disorder (40 mg, n=46; 80 mg, n=75).

Remington G, et al. ACNP 2016; Hollywood, FL.

TARDIVE DYSKINESIA

## KINECT, KINECT 3, & KINECT 4 Pooled Long-term Safety Analysis: AEs

	VBZ Dos	e Groups	All
	40 mg (n=200)	80 mg (n=230)	Participants (n=430)
Summary of AEs, %			
Any TEAE	61.0	71.3	66.5
Any serious AE*	11.5	16.5	14.2
Discontinuation due to AE	16.0	13.5	14.7
AEs leading to dose reduction	5.0	8.3	6.7
TEAEs by preferred term, $\%^{\dagger}$			
Headache	7.0	8.3	7.7
Urinary tract infection	7.5	7.4	7.4
Somnolence	7.5	5.2	6.3
Fatigue	7.0	3.5	5.1
Suicidal ideation <sup>‡</sup>	4.5	4.8	4.7
Dizziness	3.0	5.2	4.2
Diarrhea	3.0	4.8	4.0
Nasopharyngitis	3.0	4.3	3.7
Constipation	3.5	3.9	3.7
Depression	5.0	2.2	3.5
Vomiting	3.5	3.5	3.5
Anxiety	3.5	3.5	3.5
Fall	3.5	3.0	3.3
Dry mouth	4.0	2.2	3.0

- Laboratory parameters were similar across treatment groups; no clinically relevant changes were identified, including liver function tests and metabolic parameters
- Some participants had a small increase in prolactin levels; approximately 20% of all participants already had elevated prolactin at baseline
- No notable ECG changes were observed

\*Serious AEs that occurred in ≥1% of all participants were schizophrenia (1.2%) and suicidal ideation (1.2%). <sup>†</sup>Reported in ≥3% of all VBZ-treated participants. <sup>‡</sup>Includes spontaneous patient-reported TEAEs and endorsements of any C-SSRS suicidal ideation category (items 1–5).

AE, adverse event; C-SSRS, Columbia-Suicide Severity Rating Scale; ECG, electrocardiogram; TEAE, treatment-emergent adverse event; VBZ, valbenazine. Remington G, et al. ACNP 2016; Hollywood, FL.